Progression of molecular-targeted drugs for hepatocellular carcinoma
LI You
HUA Haiqing
Abstract：Primary liver carcinoma is one of the most common malignancies in China, which is marked by its insidious onset and rapid progression. Most of the cases are unresectable when detected, making the prognosis extremely poor. As the one and only mo-lecular-targeted drug which can bring about survival benefit for advanced hepatocellular carcinoma, sorafenib has aroused a mass re-search fervor of molecular-targeted drugs since 2007, the year it appeared on the market. Regrettably, no new drugs are available for clinical use. This review focuses on central questions regarding molecular-targeted drugs in clinical study for hepatocellular carcinoma.
Keywords：Primary liver cancerHepatocellular carcinomaAnti-angiogenesis treatmentTargeting immunotherapy
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：7( 462-468 )